Anshul has over 20 years of experience in the pharmaceutical and biotech industries as a general manager, management consultant, commercial leader and entrepreneur. Most recently, he served as Chief Commercial Officer and EVP of Peri and Post-Approval Services at PPD. He started his career at PPD as Global Head of PPD Biotech and under his leadership PPD became a market leader for CRO services in the Biotech segment. Before PPD, Anshul ran the global life sciences business unit at Gerson Lehrman Group (GLG), where he created a customer business model to serve the pharmaceutical and biotechnology industries. Prior to GLG, he worked at McKinsey, where he was an associate principal in the health care practice. He currently serves on the boards of TriNetX, Saama Technologies, Orsini Specialty Pharmacy and Opthea Ltd. (observer).
Anshul earned his B.S and M.S.E in Biomedical Engineering from Johns Hopkins University and his MBA from the Wharton School at the University of Pennsylvania.
Aaron has 18 years of experience in the pharmaceutical and biotech industries as a biostatistician. Most recently, Aaron served as Global Head of Biostatistics at ICON. At ICON, he managed a global team of 55 biostatisticians and provided statistical oversight for more than 100 oncology trials. Before ICON, Aaron worked as a biostatistician at PPD for 13 years with a focus on oncology and auto-immune therapeutic areas and an emphasis on program development and adaptive designs.
Aaron served in the US Army for 4 years and in the Texas National Guard for 4 years. He earned his B.S. in Mathematics from the University of Texas – San Antonio and his M.S. in Statistical Science from Southern Methodist University.
Milena has over 24 years of experience in clinical research, people, and team management delivering portfolios across multiple therapeutic indications in all stages of drug development as a strategic development lead, operational expert, and as a medical advisor. Milena has provided consultations to clients on the drug development process, due diligence, risk assessment and mitigation strategies as well as study and product development plans. Milena has served as the operational and strategy lead on operational and executive steering committees for partnerships in various indications and geographies and has successfully led start-up operations in new countries in EMEA as a clinical research manager and country manager. Milena has a proven record for delivering complex programs and creating, motivating, and leading multi-national teams in EMEA, Asia and the Americas. During her time as Chief Compliance Officer, Milena was involved in setting up quality standards and systems on a company level and hosting numerous agency inspections in Europe, North America, and MENA.
Milena was recognized as Top 25 Women Leaders in Biotechnology in October 2021.
James has close to 30 years professional experience in the pharmaceutical and CRO industries, working across a range of disciplines including academic research, clinical development, corporate development and investing. He works with the Abingworth investment team to source and evaluate new clinical co-development (CCD) investment opportunities and supports existing CCD investments.
Prior to joining Abingworth and Launch Therapeutics, James was Chief Business Officer at Nuvelution, a specialist CCD investment company. Before Nuvelution, he was with IQVIA as head of corporate development and regional board member for the Asia Pacific region, and previously with NovaQuest, Quintiles internal investment group, where he led multiple investments in Europe and the USA. James started his career in clinical research with positions of increasing responsibility at GSK, before moving to Quintiles in global operations and sales roles. He is a founder at Ninnion LLC and President US-Asia Pharma Advisory LLC.
James has a BSc in Pharmacology and a PhD in Neuropharmacology from the University of Bristol, UK, where he published over twenty peer reviewed papers. He completed postgraduate training in Executive Leadership, from the University of North Carolina Kenan Flagler Business School.
Elisha has over 25 years of drug development experience. Elisha spent the last 14 years at PPD where she was most recently Head of Development Operations. In this role, she had global accountability for a $3.5B clinical trial portfolio. Elisha also led the team who developed and executed a COVID-19 vaccine program, achieving first time in man to emergency use authorization in less than 11 months. Elisha is recognized for generating and implementing innovative, strategic solutions. She is a founding member of PPD Biotech and led the creation and implementation of an industry-leading Biotech operating model which resulted in improved project cycle times and significant business expansion. Before PPD, Elisha led the Infectious Disease and Biotech project management teams at Covance (now Labcorp Drug Development).